Liquid biopsy provides new insights into gastric cancer
Metrics: PDF 2030 views | HTML 2940 views | ?
Camila Tavares Uchôa Guimarães1,*, Nina Nayara Ferreira Martins2,*, Kelly Cristina da Silva Oliveira2, Caroline Martins Almeida1, Thayanne Macedo Pinheiro2, Carolina Oliveira Gigek3,4, Sandro Roberto de Araújo Cavallero2, Paulo Pimentel Assumpção2, Marília Arruda Cardoso Smith3, Rommel Rodríguez Burbano2,5 and Danielle Queiroz Calcagno1,2
1Residência Multiprofissional em Oncologia, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brazil
2Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, PA, Brazil
3Disciplina de Genética, Universidade Federal de São Paulo, São Paulo, SP, Brazil
4Disciplina de Gastroenterologia Cirurgica, Universidade Federal de São Paulo, São Paulo, SP, Brazil
5Laboratório de Biologia Molecular, Hospital Ophir Loyola, Belém, PA, Brazil
*These authors contributed equally to this work
Danielle Queiroz Calcagno, email: [email protected]
Keywords: circulating tumor cells; circulating tumor DNA; circulating microRNAs; circulating long non-coding RNAs; precision medicine
Received: July 26, 2017 Accepted: December 01, 2017 Epub: February 21, 2018 Published: March 13, 2018
Liquid biopsies have great promise for precision medicine as they provide information about primary and metastatic tumors via a minimally invasive method. In gastric cancer patients, a large number of blood-based biomarkers have been reported for their potential role in clinical practice for screening, early diagnosis, prognostic evaluation, recurrence monitoring and therapeutic efficiency follow-up. This current review focuses on blood liquid biopsies' role and their clinical implications in gastric cancer patients, with an emphasis on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and circulating non-coding RNAs (ncRNAs). We also provide a brief discussion of the potential and limitations of liquid biopsies use and their future use in the routine clinical care of gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.